7-Eleven, Inc. is Dishing Out Thanksgiving Week Deals Worth Gobbling Up

Convenience and savings are the main courses at 7-Eleven® this Thanksgiving Thanksgiving week is almost here, and the celebration at 7-Eleven, Inc. goes far beyond the dinner table. Participating 7-Eleven®, Speedway®and Stripes®stores are rolling out exclusive offerings made for every moment of the holiday week – from deals on fan-favorite meals to free delivery and […]

Pomerantz LLP Notifies Investors of Class Action Against aTyr Pharma, Inc. – ATYR

NEW YORK CITY, NY / ACCESS Newswire / November 17, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ:ATYR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

Glucose Biosensors Market Size Worth USD 23.08 Billion by 2034

Glucose Biosensors Market Size Worth USD 23.08 Billion by 2034 According to Precedence Research, the global glucose biosensors market size will grow from USD 10.71 billion in 2025 to nearly USD 23.08 billion by 2034, with an expected CAGR of 8.91% from 2025 to 2034. North America held the largest 34% share in 2024, while

Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies

SEATTLE, Nov. 17, 2025 (GLOBE NEWSWIRE) — Pluristyx announced today the launch of a project up to $1.4 million, supported and funded by Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization. The project will create and distribute a genetically engineered induced pluripotent stem cell (iPSC) line, providing developers

Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies

Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies The up to $1.4M collaboration will enable manufacturing “universal” islets containing a drug-inducible safety feature designed to make curative therapies accessible without the need for chronic immunosuppression GlobeNewswire November 17, 2025 SEATTLE, Nov. 17, 2025 (GLOBE

Caring Senior Service deepens Arizona roots with third state location

Phoenix Central owner Julie Stelianides brings personal experience and professional insight to expanding home care options for seniors in the area Caring Senior Service, a non-medical, personalized home care services company, announced today it has opened its third location in Arizona at 2345 E. Thomas Road, Suite #204, in Phoenix. https://mma.prnewswire.com/media/2823983/Caring_Senior_Service_Julie_Stelianides.jpg After observing firsthand the

JinkoSolar Announces Second and Third Quarter 2025 Financial Results

JinkoSolar Holding Co., Ltd. (“JinkoSolar” or the “Company”) (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced its unaudited financial results for the second quarter ended June 30, 2025 and third quarter ended September 30, 2025. Third Quarter 2025 Business Highlights — Total module shipments for the

JSPR DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Jasper Therapeutics, Inc. Investors to Join the Class Action Lawsuit

NEW YORK CITY, NY / ACCESS Newswire / November 17, 2025 / Attorney Advertising Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. ("Jasper" or "the Company") (NASDAQ:JSPR) and certain of its officers. Class Definition This lawsuit seeks to recover

MRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Marex Group plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / November 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marex Group plc ("Marex" or "the Company") (NASDAQ:MRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against

Pomerantz LLP Calls Attention to Class Action Against CarMax, Inc. – KMX

NEW YORK CITY, NY / ACCESS Newswire / November 17, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against CarMax, Inc. ("CarMax" or the "Company") (NYSE:KMX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

Scroll to Top